Page 9, Is The Drug Industry Asleep At The Wheel Regarding Insomnia? Indiplon will be the clear winner partly due to a better product marketing label and Pfizer as a power house marketing partner. Indiplon FY2007 sales projected @ $1.2 BILLION by some analyst and growing. That equates to Huge earnings for NBIX as its a 50/50 partnership in North America. SEPR Estorra Sales 04, $50M 05, $150M 06, $300M 07, $400m NBIX Indiplon 05, $250M 06, $647M 07, $1.2Billion
Indiplon FY07 projected sales are $1.2 Billion, Frogs you know that is just the tip of the iceberg when you have a U.S. market of over 50 million people who suffer from some form of Insomnia. On a simple valuation model of 10X sales and 50/50 revenue split that equates to about a $180 share price. If I did an earnings calculation @ a 35 multiple its much higher about $225. Thats just the valuation of Indiplon it has lots of cash and a very strong robust product pipeline. Its a stock we can all retire on.